Insider · CIK 0001771423
Ann Calby Miller
Files at INO (INOVIO PHARMACEUTICALS, INC.). First filing -, latest -.
Ann Calby Miller files SEC Form 4 as director at INO (INOVIO PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ann Calby Miller has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Common Stock Optionsderivative | +41,800 | $0.00 | $0 | 41,800 | May 21, 2026 |
| May 20, 2026 | INO INOVIO PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +34,200 | $0.00 | $0 | 34,200 | May 21, 2026 |
| May 21, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Common Stock | +2,167 | - | - | 9,877 | May 21, 2025 |
| May 21, 2025 | INO INOVIO PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative | -2,167 | $0.00 | $0 | 0 | May 21, 2025 |
Questions about Ann Calby Miller
Answered from the filings on this page, as of the latest one.
Is Ann Calby Miller buying or selling?
Ann Calby Miller has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ann Calby Miller's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ann Calby Miller has 0.
Where does Ann Calby Miller file Form 4?
Ann Calby Miller has filed Form 4 at INO (INOVIO PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.